Wednesday, September 24, 2014 5:55:23 PM
There are three purple links in my post #17980 which I link below. Each one leads to a webpage that further details the FCPA issue by people who study this. HDY's situation is not unique, these FCPA's are a horror show, and far from cut and dry. The DOJ basically cares ZERO about Statute of Limitations (SOL).
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106550513'
Is this information from HDY or an assumption? As they are cooperating, it is quite likely they have in fact done so. Read the links, and you will see why they like have done so, to demonstrate full cooperation.
You're missing my point. SOL only becomes relevant as a defense once there is a criminal indictment. A criminal indictment would be a disaster for HDY, it wouldn't matter to shareholders if it resulted in a conviction or not, the only exploration PSC would expire, as would HDY.
HDY will cooperate in every way to avoid this, and their high powered lawyers would know better than to even mention SOL to the DOJ.
Thus HDY would bend over backward to cooperate, and not even talk about SOL to the DOJ.
These FCPA investigations have no SOL, they are usually settled outside of court with no charges filed. Quite often for events well beyond the 5 and 8 year SOL.
I don't believe so either. They are spending the exorbitant legal fees demonstrating cooperation, and hoping this leads to a quicker resolution.
That is possible, and perusing my links and researching the matter one will see that it could also be a matter more than five years from the start of the investigation. This is not especially a concern of the DOJ, this is a game of chicken, which they win easily.
When the event(s) being investigated occurred is really a moot point at this stage. It would only ever be an issue after a criminal indictment, at which point HDY would be finished. Thus relevant only to those facing the criminal charges.
"Games are won by players who focus on the playing field -- not by those whose eyes are glued to the scoreboard." - Warren Buffett
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM